Cantor Fitzgerald on Akero Therapeutics (AKRO), 'we expect the stock to trade down'
Tweet Send to a Friend
Cantor Fitzgerald analyst Prakhar Agrawal reiterated an Overweight rating and $69.00 price target on Akero Therapeutics (NASDAQ: AKRO)The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
